- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02205723
Smartphone-facilitated Asthma Control (SNAPP)
Smartphone-facilitated Medication Notification for Asthma Control in Pediatric Patients (SNAPP) Pilot Study
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The objective of this protocol is to pilot an innovative approach to medication adherence to determine if such an approach will improve inhaled corticosteroid (ICS) medication adherence, a critical gap in improving the health of children with asthma.
Acute asthma exacerbations occur yearly in almost 60% of children with asthma. They are the most frequent reason for childhood hospitalization and the most expensive component of pediatric asthma care in the U.S. Exacerbations impair quality of life and disproportionately affect African-American children, children with Medicaid insurance, and the poor. Up to 70% of exacerbations are preventable if guideline-recommended inhaled corticosteroid (ICS) medication adherence is achieved. However, ICS medication adherence in children with persistent asthma is dismal at only 11 - 18%. Amongst children with Medicaid insurance prescribed ICS, 63% discontinue the medication within 90 days. As a healthcare system, investigators have been unable to meaningfully improve ICS medication adherence in a cost-efficient way for patients with asthma, and particularly for the high-risk, highest-potential population of children with moderate or severe persistent asthma. These children suffer the greatest morbidity and mortality from asthma yet have highest-potential to benefit from improved ICS medication adherence. There is an urgent need for an efficacious adherence intervention for this population because, without it, these children will continue to experience impaired health and disproportionate morbidity.
The investigators' long-term objective is to identify and disseminate an intervention that will minimize the occurrence and severity of exacerbations in this population. The overall objective of this pilot study is to test the feasibility of Smartphone-facilitated medication Notification for Asthma Control in Pediatric Patients (SNAPP) using a wireless medication monitor (WMM) and smartphone application that provides parents reminders for administration of ICS medication, real-time feedback on preventive and controller medication adherence, and wireless upload of this data to a secure online database. The central hypothesis is that for children in this population, SNAPP will result in >=25% improved Asthma Control Test (ACT) scores in comparison with usual management. Secondary hypotheses are that the intervention will result in a >= 30% decrease in FeNO in comparison with usual care at 6 months and >=40% increase in ICS medication adherence at 6 months. The central hypothesis has been formulated on the basis of reports that parents of children with acute exacerbations continue to have insufficient knowledge of asthma self-management yet are motivated to do what is best for their child. SNAPP incorporates monitoring, reminders, and dynamic feedback through a smartphone that will improve ICS medication adherence and that will influence the child's future independence and chronic disease-management skills. Importantly, the investigators will use wireless medication monitors to accurately and objectively ascertain ICS medication adherence without patient effort. Parents are facile with and use wireless technology to organize their daily activities and for communicating. Incorporating this technology into health care and medication adherence is a logical next-step.
The investigators propose to test the hypotheses through the following Aim: To determine whether SNAPP meaningfully improves 6-month asthma control measured with the Asthma Control Test, airway inflammation measured using exhaled nitric oxide and ICS adherence compared with usual care, in an RCT of children with moderate or severe persistent asthma.
Studietype
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37232
- Vanderbilt Children's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- TennCare Medicaid insurance, and an acute exacerbation (45% of our ED patients with acute asthma, section C.11.)
- Parent has a smartphone and wireless account that they agree to use for this study (if randomized to intervention group), anticipated residence in the Nashville Metropolitan Service Area for at least 12 months, willingness to participate in phone-based (wireless or landline) ACT-scoring monthly, and willingness to return at 3, 6 and 12 months for FeNO testing.
- The participant's PCP agrees that patient has moderate or severe persistent asthma and should be on ICS for at least the subsequent 12 months in accordance with NIH-NAEPP expert panel guidelines.87,88
Exclusion Criteria:
- Exclusion criteria include prior study enrollment, other medical condition contributing to respiratory distress (e.g., pneumonia, cystic fibrosis) or other diseases that may necessitate treatment with systemic corticosteroid (CCS; e.g., nephrotic syndrome).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: Kontroll
Kontrollgruppe
|
Asthma teaching
Andre navn:
|
Eksperimentell: Smartphone Asthma Control
|
Asthma teaching
Andre navn:
Smartphone Asthma Control
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Childhood asthma control test
Tidsramme: 6 months
|
Measurement of change of C-ACT at 6 months.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Fractional excretion of exhaled nitric oxide
Tidsramme: 6 months
|
Measurement of change of FeNO at 6 months.
|
6 months
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Donald H Arnold, MD, MPH, Vanderbilt University
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- IRB 140934
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Astma hos barn
-
Hospices Civils de LyonHar ikke rekruttert ennåEarly Childhood Caries (ECC)Frankrike
-
National Cancer Institute (NCI)FullførtUbehandlet barnehjernestammegliom | Ubehandlet Childhood Anaplastic Astrocytoma | Ubehandlet Childhood Anaplastic Oligodendroglioma | Ubehandlet gigantcelleglioblastom i barndommen | Ubehandlet glioblastom i barndommen | Ubehandlet Childhood Gliomatosis Cerebri | Ubehandlet Childhood Gliosarcoma | Ubehandlet...Forente stater
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtChildhood Infratentorial Ependymoma | Supratentorial ependymom i barndommen | Nylig diagnostisert Childhood EpendymomaForente stater
-
University of UtahJazz Pharmaceuticals; Alternating Hemiplegia of Childhood FoundationFullførtAlternerende Hemiplegia of ChildhoodForente stater
-
Institut National de la Santé Et de la Recherche...FullførtAlternerende Hemiplegia of ChildhoodFrankrike
-
Assistance Publique - Hôpitaux de ParisHar ikke rekruttert ennåAlternerende Hemiplegia of ChildhoodFrankrike
-
University Hospital, BrestRekrutteringPsykotisk lidelse | Psykose av Childhood BorderlineFrankrike
-
Children's Oncology GroupNational Cancer Institute (NCI)FullførtStage I Childhood Hodgkin-lymfom | Fase II Hodgkin-lymfom hos barn | Utarming av lymfocytter i barndommen Hodgkin-lymfom | Childhood Mixed Cellularity Hodgkin-lymfom | Nodulær sklerose i barndommen Hodgkin lymfom | Barndommens gunstige prognose Hodgkin lymfomForente stater
-
National Cancer Institute (NCI)FullførtGlioblastom | Gliosarkom | Anaplastisk astrocytom | Ubehandlet barnehjernestammegliom | Kjempecelleglioblastom | Ubehandlet Childhood Anaplastic Astrocytoma | Ubehandlet gigantcelleglioblastom i barndommen | Ubehandlet glioblastom i barndommen | Ubehandlet Childhood Gliosarcoma | Hjernestamgliom | Ubehandlet... og andre forholdForente stater
-
Hospices Civils de LyonFullført
Kliniske studier på Asthma teaching in ER
-
Hopital MontfortInstitut du Savoir MontfortFullførtGrunnleggende livsstøtteCanada
-
Ottawa Hospital Research InstituteFullført
-
Aydin Adnan Menderes UniversityHar ikke rekruttert ennå
-
Aydin Adnan Menderes UniversityHar ikke rekruttert ennåUtdanning | SykepleierstudenterTyrkia
-
Hamilton Health Sciences CorporationUkjent
-
First Affiliated Hospital of Chongqing Medical...Aktiv, ikke rekrutterende
-
Birmingham Women's NHS Foundation TrustFullførtKvinne bekkenundersøkelseStorbritannia
-
HK inno.N CorporationUkjent
-
HK inno.N CorporationFullførtParenteral ernæringKorea, Republikken
-
BlueWillow BiologicsPorton Biopharma Ltd.Fullført